Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171483 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00171483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00171483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2004
Completion date
April 30, 2005
Enrollment
30
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease (gerd)